IN8BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
IN8BIO, INC. (INAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 5.72 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 1.46K shares.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 4.26K shares, a 19.44% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 1.73K shares, a 99.54% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 4.87K shares, a 99.13% decline year-over-year.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 8.38K shares, a 99.15% decline from fiscal 2024.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 988.93K shares, a 224.84% increase from fiscal 2023.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 304.44K shares, a 232.58% increase from fiscal 2022.
- IN8BIO, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 91.54K shares, a 37.33% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.46K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 5.72K shares 10-Q · filed 2026-08-06 | 7.46K shares derived: sum of 3 quarters · filed 2026-08-06 | 12.33K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 4.26K shares 10-Q · filed 2026-05-07 | 5.99K shares derived: sum of 2 quarters · filed 2026-05-07 | 10.86K shares derived: sum of 3 quarters · filed 2026-05-07 | 7.35K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 1.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 6.60K shares derived: sum of 2 quarters · filed 2026-03-12 | 3.09K shares derived: sum of 3 quarters · filed 2026-03-12 | 8.38K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 4.87K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 1.36K shares derived: sum of 2 quarters · filed 2025-11-06 | 6.65K shares 10-Q · filed 2025-11-06 | 383.31K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | -3.51K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.78K shares 10-Q · filed 2025-08-07 | 378.44K shares derived: sum of 3 quarters · filed 2025-08-07 | 940.37K shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 5.29K shares 10-Q · filed 2025-05-07 | 381.95K shares derived: sum of 2 quarters · filed 2025-05-07 | 943.88K shares derived: sum of 3 quarters · filed 2025-05-07 | 943.88K shares derived: sum of 4 quarters · filed 2025-05-07 |
| 2024-12-31 | 376.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 938.59K shares derived: sum of 2 quarters · filed 2025-03-13 | 938.59K shares derived: sum of 3 quarters · filed 2025-03-13 | 988.93K shares 10-K · filed 2025-03-13 |
| 2024-09-30 | 561.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 561.93K shares derived: sum of 2 quarters · filed 2024-11-12 | 612.27K shares 10-Q · filed 2024-11-12 | 747.66K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 50.34K shares 10-Q · filed 2024-08-08 | 185.73K shares derived: sum of 3 quarters · filed 2024-08-08 | 185.73K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 50.34K shares 10-Q · filed 2024-05-09 | 185.73K shares derived: sum of 2 quarters · filed 2024-05-09 | 185.73K shares derived: sum of 3 quarters · filed 2024-05-09 | 185.73K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 135.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 135.40K shares derived: sum of 2 quarters · filed 2024-03-14 | 135.40K shares derived: sum of 3 quarters · filed 2024-03-14 | 304.44K shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-09 | 169.04K shares 10-Q · filed 2023-11-09 | 186.58K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 169.04K shares 10-Q · filed 2023-08-10 | 186.58K shares derived: sum of 3 quarters · filed 2023-08-10 | 196.83K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 169.04K shares 10-Q · filed 2023-05-12 | 186.58K shares derived: sum of 2 quarters · filed 2023-05-12 | 196.83K shares derived: sum of 3 quarters · filed 2023-05-12 | 196.83K shares derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | 17.54K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 27.79K shares derived: sum of 2 quarters · filed 2023-03-30 | 27.79K shares derived: sum of 3 quarters · filed 2023-03-30 | 91.54K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 10.25K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 10.25K shares derived: sum of 2 quarters · filed 2022-11-10 | 74.00K shares 10-Q · filed 2022-11-10 | 92.33K shares derived: sum of 4 quarters · filed 2022-11-10 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 63.75K shares 10-Q · filed 2022-08-12 | 82.08K shares derived: sum of 3 quarters · filed 2022-08-12 | 209.80K shares derived: sum of 4 quarters · filed 2022-08-12 |
| 2022-03-31 | 63.75K shares 10-Q · filed 2022-05-12 | 82.08K shares derived: sum of 2 quarters · filed 2022-05-12 | 209.80K shares derived: sum of 3 quarters · filed 2022-05-12 | |
| 2021-12-31 | 18.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 146.06K shares derived: sum of 2 quarters · filed 2022-03-17 | 146.06K shares 10-K · filed 2022-03-17 | |
| 2021-09-30 | 127.72K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 127.72K shares 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B |